Systemic therapy for relapsed small cell lung cancer

Systemic therapy is typically offered to patients with adequate PS to tolerate toxicities of treatment (eg, ECOG PS 0, 1, or 2). Those with worsened PS, at any point in treatment, are typically offered palliative treatments, which may include pain control, palliative radiation, and/or hospice care.

PS: performance status; ECOG: Eastern Cooperative Oncology Group; SCLC: small cell lung cancer.
* Patients with baseline neuropathy, heart failure, hearing loss, renal failure, or frailty (ECOG PS 2 or more) are unlikely to tolerate platinum-based doublet chemotherapy.
¶ Some UpToDate contributors also continue maintenance immunotherapy, along with chemotherapy.
Δ Alternatives include irinotecan or temozolomide.
◊ Although lurbinectedin has not been directly compared with the camptothecins, it has a milder toxicity profile, and is therefore preferred, if available.
§ Treatment options will depend on what the patient previously received. For example, if the patient has not yet received a camptothecin, this would be the preferred option. A number of other agents, including the taxanes, vinorelbine, gemcitabine, and temozolomide, have shown activity in patients with relapsed SCLC.

Graphic 129498 Version 3.0

خرید پکیج

Systemic therapy for relapsed small cell lung cancer